GHK-Cu

A decently reviewed face cream whose maker also claims it can regrow organs. The part where it makes skin look a bit better has some real human testing behind it, though modest and not always confirmed. The grand regeneration story is a lab-bench idea that has never been properly tested in people.

GHK is a copper-binding tripeptide that complexes Cu(II). It is thought to act as a signalling matrikine and copper carrier. Proposed actions include stimulating dermal fibroblast synthesis of collagen, elastin, glycosaminoglycans and proteoglycans (e.g. decorin), modulating matrix metalloproteinases and their inhibitors to remodel the extracellular matrix, and upregulating growth factors (TGF-beta, VEGF, bFGF) implicated in angiogenesis and tissue repair. Copper appears required for most effects; chelating it abolishes activity in vitro. Gene-expression profiling suggests broad transcriptional modulation toward repair and away from inflammation, though this is predominantly in-vitro, computational and animal data. Topically it is delivered in creams and serums (copper tripeptide-1). Grey-market products are also offered for injection, a route with no controlled human evidence.

Research contexts. Not proven uses, and not recommendations.

Genuine but limited, modest and mixed, and almost entirely topical. The best-known supportive data are Leyden's 2002 controlled cosmetic trials of a GHK-Cu facial cream (approximately 71 women) and eye cream (approximately 41 women) in photoaging, reporting improved skin density and thickness and reduced fine lines and wrinkling versus comparators. A controlled study of topical copper tripeptide on CO2-laser-resurfaced skin (Miller et al. 2006, 13 completers) found no statistically significant objective improvement in erythema, wrinkles or overall skin quality; only patient-reported satisfaction was higher. These trials were small, of modest effect size and several industry-associated, but they are real human data. The dramatic mechanistic claims (collagen super-stimulation, multi-thousand-gene resets, systemic wound healing, neural and whole-body anti-ageing) come overwhelmingly from laboratory and preclinical studies. There are no controlled human efficacy or safety trials for injected or systemic GHK-Cu.

• !Topical evidence is modest, dated and partly industry-linked; effect sizes are small, results are mixed (at least one controlled trial was objectively negative), and few modern independent RCTs exist
• !Injectable and systemic GHK-Cu sold online has no controlled human efficacy or safety data. Claims of 'whole-body regeneration' and gene 'resetting' extrapolate from cell, animal and computational work
• !Grey-market injectable 'research chemical' products carry the usual risks: unverified identity and purity, sterility and endotoxin contamination, and unknown copper exposure
• !Excess systemic copper is toxic. Injecting a copper-loaded peptide raises a theoretical risk of copper overload not present with low-level topical cosmetics
• !Marketing routinely conflates impressive lab biology with proven human benefit, a key honesty gap
• !Sensitisation and irritation possible with some topical formulations

In the UK, copper tripeptide-1 (GHK-Cu) is widely used and accepted as a cosmetic ingredient, regulated under the GB Cosmetic Products Regulation (retained EU Regulation 1223/2009). Each finished cosmetic requires a Cosmetic Product Safety Report. It is not a licensed medicine. There is no MHRA marketing authorisation and no NHS or NICE endorsement for treating skin ageing, hair loss or any medical condition. Cosmetics may only make appearance-related claims. A product making medicinal claims, or any injectable GHK-Cu preparation, falls outside cosmetic rules and would be treated by the MHRA as an unlicensed medicine. Injectable GHK-Cu is typically sold as an unlicensed 'research chemical' labelled 'not for human consumption' and is not approved for human use.

1. 01
   Leyden et al. clinical trials of a topical GHK-Cu facial cream and eye cream in photoaging (presented at the American Academy of Dermatology, 2002) — Leyden J, et al., American Academy of Dermatology meeting / cosmetic trial reports (2002)

   Small controlled facial-cream (~71) and eye-cream (~41) photoaging trials; the principal anchor of clinical confidence in topical GHK-Cu. Conference-era data not indexed as a peer-reviewed paper, so treat it as such and verify the primary record.

2. 02
   Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin — Miller TR, Wagner JD, Baack BR, Eisbach KJ, Archives of Facial Plastic Surgery 8(4):252-259 (2006)

   Controlled human study (13 completers). Found NO statistically significant objective improvement in erythema, wrinkles or skin quality; only patient-reported satisfaction was higher. Important counterweight to the positive topical claims.

3. 03
   Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Pickart L, Margolina A, International Journal of Molecular Sciences 19(7):1987 (2018)

   Major review summarising mechanism, gene-expression and tissue-repair data; lead author is closely affiliated with the molecule, so read with that conflict in mind. Largely preclinical/computational.

4. 04
   Skin Regenerative and Anti-Cancer Actions of Copper Peptides — Pickart L, Vasquez-Soltero JM, Margolina A, Cosmetics (MDPI) 5(2):29 (2018)

   Review of copper-peptide biology; largely in-vitro/animal mechanistic evidence, author-affiliated.